Dr Ulrich Dauer joins group from OMEICOS

" /> Dr Ulrich Dauer joins group from OMEICOS

" />

Please login to the form below

Not currently logged in
Email:
Password:

Germany's Ventaleon names biotech entrepeneur CEO

Dr Ulrich Dauer joins group from OMEICOS

Ulrich DauerGauting, Germany-based pharma firm Ventaleon has appointed Dr Ulrich Dauer - a biotech executive and entrepreneur - as its chief executive officer at a time when the company enters late-stage clinical development.

Dauer has several years of senior executive management experience serving Activaero - a private German pharma firm now owned by Vectura - as its chief strategy officer and subsequently at Berlin-based OMEICOS Therapeutics where he was chief executive officer.

He said: “I know Ventaleon’s technology very well from my time at Activaero and believe that the novel inhaled antiviral agents that Ventaleon is developing has the potential to help patients suffering from serious infections such as influenza to get better, faster.

“I very much look forward to growing the company and advancing it into the next stages of development.”

Prior to his time at Activaero, Dauer founded 4SC AG, a biopharmaceutical company that focuses on cancer treatments, and served as its CEO for fourteen years.

Jean Luechinger, chairman of Ventaleon’s supervisory board, said: “We are very pleased to have Dauer lead Ventaleon.

“He is joining the company at a critical time as it advances into late-stage clinical development.

“With many years of effectively leading biotechs, forming strong collaborations with the pharmaceutical industry and successfully completing major financial transactions, Dauer has the ideal skill set to take Ventaleon to the next stage of growth.”

Dauer succeeds Gerhard Scheuch who will continue to serve as a member of the supervisory board of Ventaleon.

5th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics